A Randomized, Double-Blind, Multicenter, Phase II Study of Retifanlimab in Combination With INCAGN02385 Anti?LAG-3 and INCAGN02390 Anti?TIM-3 as First-Line Treatment in Participants With PD-L1?Positive CPS ? 1 Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Brief Summary

Type:
Head and Neck Cancers

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT05287113

Study #:
STUDY00149002

Start Date:
May 04, 2023

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT05287113

View Complete Trial Details & Eligibility at ClinicalTrials.gov